Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pozzuoli – page 94

1 231 clinical trials in Pozzuoli, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pozzuoli at a glance
1 231
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 231 trials in Pozzuoli

Open in trial search

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+1

Not recruiting

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not recruiting

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3116
  • Sponsor:Deciphera Pharmaceuticals Inc.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Major depression

Not recruiting

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agomelatine
  • Sponsor:Universitair Medisch Centrum Utrecht

Metastatic malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Systemic lupus erythematosus

Not recruiting

Study on Frexalimab for Treating Active Systemic Lupus Erythematosus in Patients

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo Universitetssykehus HF

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Lung disorder

Not recruiting

Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Oslo Universitetssykehus HF

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Pozzuoli

What the registry says about research in the country

01 Neoplasms

Clinical trial activity in Località la Schiana, Pozzuoli is strongly focused on cancer research, with studies examining how to improve treatment options for several advanced solid tumors. The main goal is to test new therapeutic strategies and refine existing combinations for better disease control and patient outcomes.

  • Colorectal cancer, including metastatic and unresectable forms
  • Metastatic castration-resistant prostate cancer
  • Metastatic renal cell carcinoma
  • Breast cancer with hormone receptor-positive, HER2-negative disease

These studies are exploring more effective ways to slow progression, overcome treatment resistance, and improve survival in patients with advanced neoplasms.

02 Digestive System Diseases

Several trials in this site concentrate on digestive system cancers, especially advanced colorectal cancer. Research is centered on evaluating treatment effectiveness and finding better options for patients whose disease has already progressed or carries specific genetic changes.

  • RAS-mutant metastatic colorectal cancer
  • RAS/BRAF wild-type metastatic colorectal cancer
  • Unresectable left-sided metastatic colorectal cancer
  • Patients with metastatic colorectal cancer

Across these studies, the focus is on improving tumor response, extending disease control, and identifying which patients may benefit most from targeted treatment approaches.

03 Analytical, Diagnostic and Therapeutic Techniques and Equipment

This research landscape also includes therapeutic techniques aimed at improving how treatments are delivered and how response is monitored. The trials are not only testing active therapies, but also looking for better ways to understand resistance, safety, and treatment benefit in real-world patients.

  • Biomarker research for resistance and treatment monitoring
  • Safety and tolerability comparisons between treatment strategies
  • Quality of life assessments during therapy
  • Therapy optimization in advanced cancer care

In this part of the research portfolio, investigators in Pozzuoli are helping shape more precise and patient-centered cancer care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.